A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies
Latest Information Update: 03 Dec 2025
At a glance
- Drugs MDX 2003 (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Modex Therapeutics Ltd
Most Recent Events
- 03 Dec 2025 New trial record